Trial · NCT03982199
Results by group200
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 200
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With First Occurrence of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV) Mediated Lower Respiratory Tract Disease (LRTD) | Arm 1: Main Cohort: Group 1: Ad26.RSV.preF and RSV preF Protein (Protein Mixture) | Case Definition-1 | 6 | Participants | |
| Number of Participants With First Occurrence of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV) Mediated Lower Respiratory Tract Disease (LRTD) | Arm 2: Main Cohort: Group 2: Placebo | Case Definition-1 | 30 | Participants | |
| Number of Participants With First Occurrence of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV) Mediated Lower Respiratory Tract Disease (LRTD) | Arm 1: Main Cohort: Group 1: Ad26.RSV.preF and RSV preF Protein (Protein Mixture) | Case Definition-2 | 10 | Participants | |
| Number of Participants With First Occurrence of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV) Mediated Lower Respiratory Tract Disease (LRTD) | Arm 2: Main Cohort: Group 2: Placebo | Case Definition-2 | 40 | Participants | |
| Number of Participants With First Occurrence of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV) Mediated Lower Respiratory Tract Disease (LRTD) | Arm 1: Main Cohort: Group 1: Ad26.RSV.preF and RSV preF Protein (Protein Mixture) | Case Definition-3 | 13 | Participants | |
| Number of Participants With First Occurrence of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV) Mediated Lower Respiratory Tract Disease (LRTD) | Arm 2: Main Cohort: Group 2: Placebo | Case Definition-3 | 43 | Participants | |
| Main Cohorts: Number of Participants With Any RT-PCR-confirmed RSV Disease | Arm 1: Main Cohort: Group 1: Ad26.RSV.preF and RSV preF Protein (Protein Mixture) | 13 | Participants | ||
| Main Cohorts: Number of Participants With Any RT-PCR-confirmed RSV Disease | Arm 2: Main Cohort: Group 2: Placebo | 43 | Participants | ||
| Main Cohorts: Respiratory Syncytial Virus (RSV) A2 Strain Neutralization Antibody Titers | Arm 1: Main Cohort: Group 1: Ad26.RSV.preF and RSV preF Protein (Protein Mixture) | Day 15 | 6761 | 95% Confidence Interval 5478 to 8346 | Titers |
| Main Cohorts: Respiratory Syncytial Virus (RSV) A2 Strain Neutralization Antibody Titers | Arm 2: Main Cohort: Group 2: Placebo | Day 15 | 516 | 95% Confidence Interval 443 to 602 | Titers |
| Main Cohorts: Respiratory Syncytial Virus (RSV) A2 Strain Neutralization Antibody Titers | Arm 1: Main Cohort: Group 1: Ad26.RSV.preF and RSV preF Protein (Protein Mixture) | Day 85 | 4963 | 95% Confidence Interval 4053 to 6077 | Titers |
| Main Cohorts: Respiratory Syncytial Virus (RSV) A2 Strain Neutralization Antibody Titers | Arm 2: Main Cohort: Group 2: Placebo | Day 85 | 602 | 95% Confidence Interval 528 to 687 | Titers |
| Main Cohorts: Respiratory Syncytial Virus (RSV) A2 Strain Neutralization Antibody Titers | Arm 1: Main Cohort: Group 1: Ad26.RSV.preF and RSV preF Protein (Protein Mixture) | Day 169 | 3057 | 95% Confidence Interval 2523 to 3703 | Titers |
| Main Cohorts: Respiratory Syncytial Virus (RSV) A2 Strain Neutralization Antibody Titers | Arm 2: Main Cohort: Group 2: Placebo | Day 169 | 552 | 95% Confidence Interval 489 to 623 | Titers |
| Main Cohorts: Respiratory Syncytial Virus (RSV) A2 Strain Neutralization Antibody Titers | Arm 1: Main Cohort: Group 1: Ad26.RSV.preF and RSV preF Protein (Protein Mixture) | Day 365 | 1546 | 95% Confidence Interval 1235 to 1936 | Titers |
| Main Cohorts: Respiratory Syncytial Virus (RSV) A2 Strain Neutralization Antibody Titers | Arm 2: Main Cohort: Group 2: Placebo | Day 365 | 341 | 95% Confidence Interval 284 to 409 | Titers |
| Revaccination Subcohorts: Respiratory Syncytial Virus (RSV) A2 Strain Neutralization Antibody Titers | Arm 3: Revaccination (ReVacc) Subcohort 1A: Ad26.RSV.preF/RSV preF Protein (Protein Mixture) | Day 15 | 5508 | 95% Confidence Interval 4695 to 6460 | Titers |
| Revaccination Subcohorts: Respiratory Syncytial Virus (RSV) A2 Strain Neutralization Antibody Titers | Arm 4: ReVacc Subcohort 2A: Placebo to Ad26.RSV.preF/RSV preF Protein Mixture | Day 15 | 421 | 95% Confidence Interval 374 to 475 | Titers |
| Revaccination Subcohorts: Respiratory Syncytial Virus (RSV) A2 Strain Neutralization Antibody Titers | Arm 5: ReVacc Subcohort 2A: Placebo to Ad26.RSV.preF/RSV preF Protein + Ad26.RSV.PreF Alone | Day 15 | 357 | 95% Confidence Interval 281 to 454 | Titers |
| Revaccination Subcohorts: Respiratory Syncytial Virus (RSV) A2 Strain Neutralization Antibody Titers | Arm 6: ReVacc Subcohort 2A: Placebo to Ad26.RSV.preF/RSV preF Protein + RSV preF Protein Alone | Day 15 | 361 | 95% Confidence Interval 291 to 448 | Titers |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03982199/results